Around the Web – Original Source: thenationalpulse.com
Pfizer Inc. entered into a Phase Three clinical trial for a new mRNA-based influenza vaccine, which will rely on the same controversial technology as the company’s COVID-19 vaccine.
The pharmaceutical giant’s clinical trial will “evaluate the efficacy, safety, tolerability and immunogenicity of the company’s quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy U.S. adults,” according to a company press release.
Citing “our experience with RNA viruses and mRNA technology,” in reference to its COVID-19 vaccines, Pfizer claimed it had gained “an even deeper understanding of the opportunity to potentially provide more efficacious vaccines,” according to Annaliesa Anderson, Ph.D., […]
Around the Web – Original Source: thenationalpulse.com
